Showing results (501-510 of 722) with videos related to

Sort By:
Pageof 73
The Lancet. Haematology|December 3, 2025
Medical tourism for cellular therapy: a clinical perspectiveChan H L Esther, Eugene Bingwen Fan, Yu Yue Hew, et al.
The Lancet. Haematology|February 10, 2025
Vodobatinib for patients with Philadelphia chromosome-positive chronic myeloid leukaemia resistant or intolerant to multiple lines of previous therapy: an open-label, multicentre, phase 1/2 trialJorge E Cortes, Dong-Wook Kim, Tapan Saikia, et al.
The Lancet. Haematology|February 7, 2025
Haploidentical peripheral blood stem cells combined with bone marrow or unrelated cord blood as grafts for haematological malignancies: an open-label, multicentre, randomised, phase 3 trialSijian Yu, Fen Huang, Na Xu, et al.
The Lancet. Haematology|March 5, 2025
Epistemic limitations of measurable residual disease in haematological malignanciesBenjamin Chin-Yee, Lucie Laplane, Pierre Sujobert
The Lancet. Haematology|January 6, 2025
Position statement on the diagnosis and management of acute leukaemia and aggressive lymphomas in pregnancyGeorgia Mills, Antonia Shand, Debra Kennedy, et al.
The Lancet. Haematology|January 12, 2025
Sovleplenib in patients with primary or secondary warm autoimmune haemolytic anaemia: results from phase 2 of a randomised, double-blind, placebo-controlled, phase 2/3 studyXin Zhao, Jing Sun, Zhihua Zhang, et al.
The Lancet. Haematology|December 7, 2024
Safety and efficacy of mitapivat in sickle cell disease (RISE UP): results from the phase 2 portion of a global, double-blind, randomised, placebo-controlled trialModupe Idowu, Lucas Otieno, Bogdan Dumitriu, et al.
The Lancet. Haematology|June 27, 2024
Molecular diagnosis of primary CNS lymphoma in 2024 using MYD88Leu265Pro and IL-10Teresa Calimeri, Nicoletta Anzalone, Maria Giulia Cangi, et al.
The Lancet. Haematology|July 21, 2024
Low dose lenalidomide versus placebo in non-transfusion dependent patients with low risk, del(5q) myelodysplastic syndromes (SintraREV): a randomised, double-blind, phase 3 trialMaría Díez-Campelo, Félix López-Cadenas, Blanca Xicoy, et al.
The Lancet. Haematology|November 1, 2023
Cusatuzumab plus azacitidine in newly diagnosed acute myeloid leukaemia ineligible for intensive chemotherapy (CULMINATE): part one of a randomised, phase 2, dose optimisation studyThomas Pabst, Cristina Papayannidis, Fatih Demirkan, et al.
Pageof 73